All In Biotech

Free tool

FAERS Monitor: Delestrogen

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 009402 or its brand name (Delestrogen, Estradiol Valerate). Reports on generic versions are filed under their own applications.

Reports

778

Serious

525

67% of reports

Hospitalization

149

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use96
  • headache72
  • drug ineffective71
  • fatigue65
  • nausea59
  • pain53
  • migraine45
  • dyspnoea42
  • weight increased39
  • diarrhoea36
  • abdominal pain30
  • anxiety30
  • arthralgia30
  • dizziness30
  • product quality issue30

Reports by year received

View as table
YearReports
200414
200510
200610
200721
200817
200913
201022
201118
201239
201311
201427
201520
201628
201728
201862
201928
202047
202155
202252
202358
202465
202577
202656

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,381 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
migraineSignal4512.79.6478
product quality issueSignal306.04.2120
weight increasedSignal394.73.5111
abdominal painSignal303.52.551
headacheSignal723.12.5104
off label useSignal963.02.5128
anxietySignal302.92.035
painSignal532.31.840
fatigueSignal652.31.846
nauseaSignal592.01.630
dyspnoeaSignal422.01.521
arthralgia302.01.413
dizziness301.61.17
diarrhoea361.51.16
drug ineffective711.51.210

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.